[go: up one dir, main page]

AR116022A1 - Compuestos heteroaromáticos como inhibidores de vanina - Google Patents

Compuestos heteroaromáticos como inhibidores de vanina

Info

Publication number
AR116022A1
AR116022A1 ARP190102432A ARP190102432A AR116022A1 AR 116022 A1 AR116022 A1 AR 116022A1 AR P190102432 A ARP190102432 A AR P190102432A AR P190102432 A ARP190102432 A AR P190102432A AR 116022 A1 AR116022 A1 AR 116022A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
group
refers
membered
Prior art date
Application number
ARP190102432A
Other languages
English (en)
Inventor
Hannes Fiepko Koolman
Martin Thomas Fleck
Cdrickx Godbout
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR116022A1 publication Critical patent/AR116022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos derivados de pirrolo[2,3-b]piridina como inhibidores de vanina, composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por la inhibición de la enzima vanina 1. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, o solvatos de este, en donde n se refiere a 1, 2 ó 3; m se refiere a 1, 2 ó 3; R¹ y R² se seleccionan, independientemente entre sí, del grupo que consiste en H, C₁₋₄-alquilo opcionalmente sustituido con 1 - 3 átomos F o C₁₋₂-alcoxi, arilo de 6 - 10 miembros sustituido por R².¹ y heteroarilo de 5 - 6 miembros sustituido por R².¹, en donde R².¹ se selecciona del grupo que consiste en H, F, Cl, Br, -CN, NR².¹.¹R².¹.², SO₂R².¹.³ y OR².¹.⁴, en donde R².¹.¹, R².¹.², independientemente entre sí, se refiere a H, C₁₋₄-alquilo o C₃₋₄-cicloalquilo; o R².¹.¹ y R².¹.², junto con el átomo de N al que están unidos, forman un heterociclilo de 4 - 5 miembros o un heterociclilo de 6 miembros que opcionalmente contiene un heteroátomo adicional seleccionado del grupo que consiste en N y O; R².¹.³ se refiere a C₁₋₄-alquilo o NR².¹.¹R².¹.²; R².¹.⁴ se selecciona del grupo que consiste en H, C₁₋₄-alquilo, C₃₋₅-cicloalquilo, heterociclilo de 4 - 5 miembros que contiene 1 heteroátomo seleccionado del grupo que consiste en N y O, en donde en la definición de R².¹.¹, R².¹.², R².¹.³ y R².¹.⁴ dicho alquilo, cicloalquilo y heterociclilo son opcionalmente sustituidos por 1 - 3 átomos de F o un C₁₋₂-alcoxi; o R¹ y R² juntos pueden formar un carbociclo de 3 - 5 miembros o un heterociclilo de 4 - 6 miembros que contiene un heteroátomo seleccionado del grupo que consiste en N y O; R³ se refiere a NR³.¹R³.²; o R³ se refiere a un grupo de la fórmula (2) ó (3), en donde X se refiere a CH₂, NRX u O; en donde RX se refiere a H o C₁₋₃-alquilo; R³.¹ se selecciona del grupo que consiste en C₁₋₄-alquil-CO- opcionalmente sustituido por 1 - 3 átomos de F, C₃₋₄-cicloalquilo o C₁₋₂-alcoxi, R³.¹.³R³.¹.⁴N-CO-, R³.¹.⁵-N-CO-, pirimidina, piridina, C₃₋₅-cicloalquil-CO- sustituido con R³.¹.¹ y R³.¹.², fenil-CO- sustituido con R³.¹.¹ y R³.¹.²; en donde R³.¹.¹, R³.¹.² se seleccionan, independientemente entre sí, del grupo que consiste en H, -CH₃, -OR³.¹.¹.¹, F y -CN; R³.¹.³, R³.¹.⁴, independientemente entre sí, se refieren a H, C₁₋₄-alquilo o C₃₋₄-cicloalquilo; o R³.¹.³ y R³.¹.⁴, junto con el átomo de N al que están unidos, forman un heterociclilo de 4 - 5 miembros o un heterociclilo de 6 miembros que opcionalmente contiene un heteroátomo adicional seleccionado del grupo que consiste en N y O; R³.¹.⁵ se selecciona del grupo que consiste en C₁₋₄-alquilo, C₃₋₅-cicloalquilo, heterociclilo de 4 - 5 miembros y C₃₋₄-cicloalquil-CH₂-; R³.¹.¹.¹ se refiere a C₁₋₄-alquilo, C₃₋₅-cicloalquilo o heterociclilo de 4 - 5 miembros; en donde en la definición de R³.¹.¹, R³.¹.², R³.¹.³, R³.¹.⁴, R³.¹.⁵ y R³.¹.¹.¹ dicho alquilo, cicloalquilo y heterociclilo son opcionalmente sustituidos por 1 - 3 átomos de F o un C₁₋₂-alcoxi; R³.² se selecciona del grupo que consiste en H, C₁₋₄-alquilo, C₃₋₄-cicloalquilo, C₃₋₄-cicloalquil-C₁₋₂-alquil y fenil-C₁₋₂-alquil-; en donde en la definición de R³.² dicho alquilo, cicloalquilo y fenilo son opcionalmente sustituidos por 1 - 3 átomos de F o un C₁₋₂-alcoxi; R⁴ se refiere a hidrógeno o C₁₋₄-alquilo opcionalmente sustituido con 1 a 3 átomos de F; o R³ y R⁴ juntos forman un heterociclo de 4 - 6 miembros que contiene un átomo de oxígeno.
ARP190102432A 2018-08-28 2019-08-27 Compuestos heteroaromáticos como inhibidores de vanina AR116022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18191082 2018-08-28

Publications (1)

Publication Number Publication Date
AR116022A1 true AR116022A1 (es) 2021-03-25

Family

ID=63442424

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102432A AR116022A1 (es) 2018-08-28 2019-08-27 Compuestos heteroaromáticos como inhibidores de vanina

Country Status (28)

Country Link
US (2) US10864201B2 (es)
EP (1) EP3844161B1 (es)
JP (1) JP7148709B2 (es)
KR (1) KR102755639B1 (es)
CN (2) CN112601748A (es)
AR (1) AR116022A1 (es)
AU (1) AU2019326933B2 (es)
BR (1) BR112021000650A2 (es)
CA (1) CA3106513A1 (es)
CL (1) CL2021000288A1 (es)
CO (1) CO2021002225A2 (es)
CR (1) CR20210101A (es)
DK (1) DK3844161T3 (es)
DO (1) DOP2021000021A (es)
EA (1) EA202190588A1 (es)
EC (1) ECSP21013743A (es)
ES (1) ES2932557T3 (es)
HU (1) HUE061186T2 (es)
IL (1) IL280898B2 (es)
JO (1) JOP20210034A1 (es)
MA (1) MA53479A (es)
MX (1) MX2021002323A (es)
PE (1) PE20210478A1 (es)
PH (1) PH12021550269A1 (es)
PL (1) PL3844161T3 (es)
SG (1) SG11202101749VA (es)
TW (1) TWI826509B (es)
WO (1) WO2020043658A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
AU2019326933B2 (en) * 2018-08-28 2024-12-05 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
MX2021006489A (es) 2018-12-03 2021-07-06 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina.
IL283397B2 (en) 2018-12-03 2025-03-01 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors
EA202191477A1 (ru) 2018-12-03 2021-10-13 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
IL301556A (en) * 2020-09-25 2023-05-01 Shanghai Meiyue Biotech Dev Co Ltd Pyrimidine carboxamide compound and its use
TWI811901B (zh) * 2020-12-17 2023-08-11 大陸商上海美悅生物科技發展有限公司 一種嘧啶甲醯胺類化合物及其應用
US20250197414A1 (en) * 2022-03-18 2025-06-19 Shanghai Meiyue Biotech Development Co., Ltd. Salt form and crystal form of vanin enzyme inhibitor, method for preparing same, and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
EP2361902A4 (en) * 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
US9585891B2 (en) 2012-09-25 2017-03-07 Merck Patent Gmbh Alpha hydroxy amides
WO2015046193A1 (ja) * 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
JP2018516254A (ja) * 2015-05-29 2018-06-21 ファイザー・インク バニン１酵素の阻害薬としての新規なヘテロ環化合物
EP3484876A1 (en) 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AU2018285131B2 (en) 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
AU2019326933B2 (en) * 2018-08-28 2024-12-05 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
IL283397B2 (en) 2018-12-03 2025-03-01 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors

Also Published As

Publication number Publication date
AU2019326933B2 (en) 2024-12-05
JP7148709B2 (ja) 2022-10-05
AU2019326933A1 (en) 2021-01-28
EA202190588A1 (ru) 2021-06-23
ES2932557T3 (es) 2023-01-20
US10864201B2 (en) 2020-12-15
CA3106513A1 (en) 2020-03-05
IL280898A (en) 2021-04-29
IL280898B1 (en) 2023-10-01
IL280898B2 (en) 2024-02-01
JP2021535154A (ja) 2021-12-16
CN113788825B (zh) 2024-06-04
CR20210101A (es) 2021-04-30
CN112601748A (zh) 2021-04-02
US20210059992A1 (en) 2021-03-04
TWI826509B (zh) 2023-12-21
EP3844161B1 (en) 2022-11-09
PH12021550269A1 (en) 2021-10-11
TW202023550A (zh) 2020-07-01
US20200069663A1 (en) 2020-03-05
MA53479A (fr) 2022-05-04
KR102755639B1 (ko) 2025-01-21
WO2020043658A1 (en) 2020-03-05
KR20210052500A (ko) 2021-05-10
CN113788825A (zh) 2021-12-14
HUE061186T2 (hu) 2023-06-28
PL3844161T3 (pl) 2023-03-13
ECSP21013743A (es) 2021-03-31
CO2021002225A2 (es) 2021-03-08
JOP20210034A1 (ar) 2021-02-25
CL2021000288A1 (es) 2021-08-20
DOP2021000021A (es) 2021-02-28
BR112021000650A2 (pt) 2021-04-13
EP3844161A1 (en) 2021-07-07
DK3844161T3 (da) 2022-12-12
PE20210478A1 (es) 2021-03-11
MX2021002323A (es) 2021-04-28
SG11202101749VA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
AR116022A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
AR117229A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
MX2021014096A (es) Compuestos heterociclicos, metodos de preparacion y usos de estos.
AR117544A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR081994A1 (es) Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR102722A2 (es) Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
PE20160540A1 (es) Inhibidores de bromodominios
AR103252A1 (es) Compuestos de quinazolina
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EA201171000A1 (ru) Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии
AR082109A1 (es) Derivados de bipiridilo
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
AR120029A1 (es) Compuestos heterocíclicos
MX373022B (es) Inhibidores de kv1.3 y su aplicacion medica.
AR097794A1 (es) Moduladores octahidro-ciclopenta[c]pirrol negativos de nr2b
AR098723A1 (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
AR125365A1 (es) Derivados de 1h-pirazol como ligandos sigma
AR112463A1 (es) Derivados de propanamina para tratar el dolor y estados relacionados con dolor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal